{"id":278,"date":"2013-11-11T08:30:22","date_gmt":"2013-11-11T08:30:22","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=278"},"modified":"2014-08-21T12:19:06","modified_gmt":"2014-08-21T11:19:06","slug":"soknadsfrister-uke-46","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2013\/11\/11\/soknadsfrister-uke-46\/","title":{"rendered":"<!--:no-->2nd Call for Global Translational Medicine Consortium (GTMC) Membership<!--:--><!--:en-->2nd Call for Global Translational Medicine Consortium (GTMC) Membership<!--:-->"},"content":{"rendered":"<p><!--:no--><\/p>\n<p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" src=\"http:\/\/d2bm3ljpacyxu8.cloudfront.net\/width\/260\/www.eutranslationalmedicine.org\/logos_EUSTM.jpg\" alt=\"\" width=\"260\" height=\"79\" \/>Global Translational Medicine Consortium (GTMC) is now accepting applications for membership. The Consortium\u2019s aim is to identify and address critical clinical needs thereby expediting translation of cutting edge research findings into novel and affordable diagnostic therapeutics and tools.<\/p>\n<p><!--:--><!--:en--><\/p>\n<p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" alt=\"\" src=\"http:\/\/d2bm3ljpacyxu8.cloudfront.net\/width\/260\/www.eutranslationalmedicine.org\/logos_EUSTM.jpg\" width=\"260\" height=\"79\" \/><br \/>\nGlobal Translational Medicine Consortium (GTMC) is now\u00a0 accepting applications for membership. The Consortium\u2019s aim is to identify and<br \/>\naddress critical clinical needs thereby expediting translation of cutting edge\u00a0 research findings into novel and affordable diagnostic therapeutics and tools.<\/p>\n<p><!--:--><!--more--><!--:no--><\/p>\n<p>Global Translational Medicine Consortium (GTMC) is now accepting applications for membership. The Consortium\u2019s aim is to identify and address critical clinical needs thereby expediting translation of cutting edge research findings into novel and affordable diagnostic therapeutics and tools.<\/p>\n<p><strong><a href=\"http:\/\/www.eutranslationalmedicine.org\/gtmc-consortium\">Visit GTMC website<\/a><\/strong><\/p>\n<p><b>Approach<\/b><\/p>\n<ul>\n<li>Establish effective collaboration between stakeholders \u00a0\u00a0\u00a0\u00a0 including academic institutions, industry partners, governments, NPOs, \u00a0\u00a0\u00a0\u00a0 funding bodies and patient organizations from various geographical regions \u00a0\u00a0\u00a0\u00a0 throughout the world.<\/li>\n<li>Initiate \u00a0\u00a0\u00a0\u00a0 joint research projects and clinical trials among consortium members.<\/li>\n<\/ul>\n<p><b>Member Benefits<\/b><\/p>\n<ul>\n<li>Access to worldwide infrastructure necessary for design, \u00a0\u00a0\u00a0\u00a0 development and performance of clinical trials and research studies.<\/li>\n<li>\u00a0Early \u00a0\u00a0\u00a0\u00a0 perspectives on potential commercialization of innovations and \u00a0\u00a0\u00a0\u00a0 discoveries.<\/li>\n<li>\u00a0Access to \u00a0\u00a0\u00a0\u00a0 clinical investigators and expertise across consortium membership.<\/li>\n<li>\u00a0 Access to \u00a0\u00a0\u00a0\u00a0 patients, clinical data and clinical samples from different geographical \u00a0\u00a0\u00a0\u00a0 locations.<\/li>\n<li>\u00a0Access to \u00a0\u00a0\u00a0\u00a0 training programs and events to share knowledge and keep updated with \u00a0\u00a0\u00a0\u00a0 current developments in the field.<\/li>\n<li>\u00a0Opportunities to \u00a0\u00a0\u00a0\u00a0 develop collaborative applications for funding.<\/li>\n<li>\u00a0 Opportunities \u00a0\u00a0\u00a0\u00a0 for joint authorships of journal articles, reviews and monographs.<\/li>\n<\/ul>\n<p><b>Eligible Applicants:<\/b><\/p>\n<p>Research groups, clinical trials coordinators,\u00a0academic institutions, companies, SMEs, service providers, funding bodies and patient organizations active in following specialty areas:<\/p>\n<ul>\n<li><b>\u00a0Oncology<\/b><\/li>\n<li><b>\u00a0Neurosciences<\/b><\/li>\n<li>\u00a0\u00a0<b>Cardiovascular \u00a0\u00a0\u00a0\u00a0 diseases<\/b><\/li>\n<li>\u00a0\u00a0<b>Respiratory diseases<\/b><\/li>\n<li>\u00a0<b>Autoimmune diseases<\/b><\/li>\n<li>\u00a0\u00a0<b>Infectious Diseases<\/b><\/li>\n<li>\u00a0 <b>Orphans\/Rare \u00a0\u00a0\u00a0\u00a0 Diseases<\/b><\/li>\n<li>\u00a0\u00a0<b>Novel \u00a0\u00a0\u00a0\u00a0 Diagnostics\/Biomarkers<\/b><\/li>\n<li>\u00a0\u00a0<b>Vaccines<\/b><\/li>\n<li><b>Data \u00a0\u00a0\u00a0\u00a0 Management<\/b><\/li>\n<\/ul>\n<p>For membership application, please provide the following information via email to the EUSTM Board at: <a href=\"mailto:info@eutranslationalmedicine.org\">info@eutranslationalmedicine.org<\/a><\/p>\n<ul>\n<li><b>\u00a0Short \u00a0\u00a0\u00a0\u00a0 profile <\/b><\/li>\n<li>\u00a0 <b>Letter \u00a0\u00a0\u00a0\u00a0 of interest<\/b><\/li>\n<li>\u00a0 <b>Specialty \u00a0\u00a0\u00a0\u00a0 area<\/b><\/li>\n<li>\u00a0\u00a0<b>Potential \u00a0\u00a0\u00a0\u00a0 capabilities\/services<\/b><\/li>\n<li>\u00a0\u00a0<b>Previous history of \u00a0\u00a0\u00a0\u00a0 consortium membership (if any)<\/b><\/li>\n<li>\u00a0\u00a0<b>Previous \u00a0\u00a0\u00a0\u00a0 history of funding\/grants (if any)<\/b><\/li>\n<li>\u00a0\u00a0<b>Full \u00a0\u00a0\u00a0\u00a0 contact details<\/b><\/li>\n<\/ul>\n<p>For more information, please visit EUSTM website:<\/p>\n<p><a href=\"http:\/\/www.eutranslationalmedicine.org\/events\"><strong>View EUSTM-2013 conference video<\/strong><\/a><!--:--><!--:en--><\/p>\n<p><strong><a href=\"http:\/\/www.eutranslationalmedicine.org\/gtmc-consortium\">Visit GTMC website<\/a><\/strong><\/p>\n<p><b>Approach<\/b><\/p>\n<ul>\n<li>Establish effective collaboration between stakeholders \u00a0\u00a0\u00a0\u00a0 including academic institutions, industry partners, governments, NPOs, \u00a0\u00a0\u00a0\u00a0 funding bodies and patient organizations from various geographical regions \u00a0\u00a0\u00a0\u00a0 throughout the world.<\/li>\n<li>Initiate \u00a0\u00a0\u00a0\u00a0 joint research projects and clinical trials among consortium members.<\/li>\n<\/ul>\n<p><b>Member Benefits<\/b><\/p>\n<ul>\n<li>Access to worldwide infrastructure necessary for design, \u00a0\u00a0\u00a0\u00a0 development and performance of clinical trials and research studies.<\/li>\n<li>\u00a0Early \u00a0\u00a0\u00a0\u00a0 perspectives on potential commercialization of innovations and \u00a0\u00a0\u00a0\u00a0 discoveries.<\/li>\n<li>\u00a0Access to \u00a0\u00a0\u00a0\u00a0 clinical investigators and expertise across consortium membership.<\/li>\n<li>\u00a0 Access to \u00a0\u00a0\u00a0\u00a0 patients, clinical data and clinical samples from different geographical \u00a0\u00a0\u00a0\u00a0 locations.<\/li>\n<li>\u00a0Access to \u00a0\u00a0\u00a0\u00a0 training programs and events to share knowledge and keep updated with \u00a0\u00a0\u00a0\u00a0 current developments in the field.<\/li>\n<li>\u00a0Opportunities to \u00a0\u00a0\u00a0\u00a0 develop collaborative applications for funding.<\/li>\n<li>\u00a0 Opportunities \u00a0\u00a0\u00a0\u00a0 for joint authorships of journal articles, reviews and monographs.<\/li>\n<\/ul>\n<p><b>Eligible Applicants:<\/b><\/p>\n<p>Research groups, clinical trials coordinators,\u00a0academic institutions, companies, SMEs, service providers, funding bodies and patient organizations active in following specialty areas:<\/p>\n<ul>\n<li><b>\u00a0Oncology<\/b><\/li>\n<li><b>\u00a0Neurosciences<\/b><\/li>\n<li>\u00a0\u00a0<b>Cardiovascular \u00a0\u00a0\u00a0\u00a0 diseases<\/b><\/li>\n<li>\u00a0\u00a0<b>Respiratory diseases<\/b><\/li>\n<li>\u00a0<b>Autoimmune diseases<\/b><\/li>\n<li>\u00a0\u00a0<b>Infectious Diseases<\/b><\/li>\n<li>\u00a0 <b>Orphans\/Rare \u00a0\u00a0\u00a0\u00a0 Diseases<\/b><\/li>\n<li>\u00a0\u00a0<b>Novel \u00a0\u00a0\u00a0\u00a0 Diagnostics\/Biomarkers<\/b><\/li>\n<li>\u00a0\u00a0<b>Vaccines<\/b><\/li>\n<li><b>Data \u00a0\u00a0\u00a0\u00a0 Management<\/b><\/li>\n<\/ul>\n<p>For membership application, please provide the following information via email to the EUSTM Board at: <a href=\"mailto:info@eutranslationalmedicine.org\">info@eutranslationalmedicine.org<\/a><\/p>\n<ul>\n<li><b>\u00a0Short \u00a0\u00a0\u00a0\u00a0 profile <\/b><\/li>\n<li>\u00a0 <b>Letter \u00a0\u00a0\u00a0\u00a0 of interest<\/b><\/li>\n<li>\u00a0 <b>Specialty \u00a0\u00a0\u00a0\u00a0 area<\/b><\/li>\n<li>\u00a0\u00a0<b>Potential \u00a0\u00a0\u00a0\u00a0 capabilities\/services<\/b><\/li>\n<li>\u00a0\u00a0<b>Previous history of \u00a0\u00a0\u00a0\u00a0 consortium membership (if any)<\/b><\/li>\n<li>\u00a0\u00a0<b>Previous \u00a0\u00a0\u00a0\u00a0 history of funding\/grants (if any)<\/b><\/li>\n<li>\u00a0\u00a0<b>Full \u00a0\u00a0\u00a0\u00a0 contact details<\/b><\/li>\n<\/ul>\n<p>For more information, please visit EUSTM website:<\/p>\n<p><a href=\"http:\/\/www.eutranslationalmedicine.org\/events\"><strong>View EUSTM-2013 conference video<\/strong><\/a><!--:--><\/p>","protected":false},"excerpt":{"rendered":"<p>Global Translational Medicine Consortium (GTMC) is now accepting applications for membership. The Consortium\u2019s aim is to identify and address critical clinical needs thereby expediting translation of cutting edge research findings into novel and affordable diagnostic therapeutics and tools. Global Translational&hellip;<\/p>\n<p class=\"more-link-p\"><a class=\"more-link\" href=\"https:\/\/k2info.w.uib.no\/en\/2013\/11\/11\/soknadsfrister-uke-46\/\">Read more &rarr;<\/a><\/p>","protected":false},"author":2783,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44,45498],"tags":[52321],"class_list":["post-278","post","type-post","status-publish","format-standard","hentry","category-nyheter","category-seminar-kurs-og-konferanser","tag-52321"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/2783"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=278"}],"version-history":[{"count":21,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/278\/revisions"}],"predecessor-version":[{"id":3994,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/278\/revisions\/3994"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}